Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · GRAIL, Inc. (GRAL)

GRAIL Q3 revenue rises 4% to $37.5 million; net loss widens 16% to $103.6 million

Mixed Impact 3 of 5 earnings Written later

GRAIL reported third-quarter 2026 results on November 4, 2026. Total revenue grew 4% to $37.5 million, but net loss widened 16% to $103.6 million and gross loss grew 32% to $18.1 million. The company said an FDA decision on Galleri is anticipated by early Q1 2027, following a favorable September Advisory Committee vote.

Key points

  • Galleri test revenue rose 14% year over year to $37.3 million, and Galleri test volume rose about 24% to more than 56,000 tests.
  • Net loss was $103.6 million, up $14.6 million, or 16%; loss per share was $(2.21), compared with $(2.46) a year earlier.
  • Adjusted gross profit fell 20% to $15.9 million, and adjusted EBITDA was $(92.6) million, an increase in loss of $20.9 million.
  • Cash, cash equivalents and short-term marketable securities totaled $788.7 million as of September 30, 2026.

The filing

CompanyGRAIL, Inc. (GRAL)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:05 PM ET
Accession number0001628280-26-070118

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.